The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Feature|Articles|April 2, 2024
- Pharmaceutical Technology, April 2024
- Volume 48
- Issue 4
- Pages: 12
Pre-Clinical Small-Scale Custom Spray Dryer
Author(s)Pharmaceutical Technology Editors
The SD-5 is the sixth custom spray dryer in operation at Serán, which aims to achieve high yields with batch sizes <50 mg of APIs.
Serán, a contract development and manufacturing organization that provides a variety of solid oral dosage forms including tablets, capsules, granules, and powder-in-bottle, has expanded its early development capabilities with the SD-5, a new pre-clinical small-scale custom spray dryer. The SD-5 is the sixth custom spray dryer in operation at Serán, which aims to achieve high yields with batch sizes <50 mg of APIs. This capability enables rapid formulation screening of spray-dried dispersions with minimal API. The SD-5’s design minimizes equipment surface area on which unrecoverable product can build up and provides containment for potent pre-tox compounds. Lead formulations can then be scaled up on Serán’s SD-45 and SD-90 spray dryers to produce larger batches and process transfer into clinical manufacturing.
Articles in this issue
over 2 years ago
The Growing Future of Drug Manufacturingover 2 years ago
Steps Towards Demystifying Risk-Based Decision Makingover 2 years ago
Development of Mini-Tablet and Multi-Unit Pellet Systemsover 2 years ago
Innovations in Prefilled Biologicsover 2 years ago
Testing the Limits of Extractables and Leachablesover 2 years ago
Making Lifecycle Management More Efficient in Europeover 2 years ago
Taking Full Advantage of Service Providersover 2 years ago
Looking at the Potential Impact of JCA on Pharmaover 2 years ago
Streamlining Variationsover 2 years ago
May I Present the NeoantigenRelated to this article
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.